ImmunityBio (NASDAQ:IBRX) Trading 8.9% Higher – Here’s What Happened

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) traded up 8.9% on Wednesday . The stock traded as high as $8.35 and last traded at $8.07. 28,840,882 shares changed hands during trading, a decline of 28% from the average session volume of 40,279,359 shares. The stock had previously closed at $7.41.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: IDMC Finds Trial Adequately Powered; supplemental BLA on track — ImmunityBio said the independent data monitoring committee confirmed the pivotal randomized BCG‑naïve NMIBC trial is adequately powered to detect the protocol’s pre‑specified benefit, and management reiterated the supplemental BLA submission is on track for 2026. That strengthens the commercial outlook for ANKTIVA and supports valuation. Article Title
• Positive Sentiment: ANKTIVA approved in Macau SAR — A regional approval increases early commercial footprints and helps revenue/proof‑of‑concept narratives for ANKTIVA outside the U.S. Article Title
• Positive Sentiment: Price target increase reported — A media report shows an analyst/coverage note lifted IBRX’s price target by ~15.6%, which can attract buyers and lend short‑term upside momentum. Article Title
• Neutral Sentiment: Coverage pieces comparing IBRX to peers — Analyst and media comparisons (e.g., vs. Moderna) highlight single‑asset risk vs. upside potential; useful context but not an immediate catalyst. Article Title
• Neutral Sentiment: Trial “power check” coverage — Media noted the trial cleared an interim power check; overlaps with the IDMC release and is supportive but redundant. Article Title
• Negative Sentiment: Widespread securities‑class action filings and solicitations — Multiple law firms (Rosen, Robbins LLP, Robbins Geller, Portnoy, Pomerantz, Block & Leviton, Kaplan Fox, etc.) have filed or announced investigations alleging securities law violations for purchases during Jan 19–Mar 24/25, 2026; these increase litigation risk, potential costs, management distraction and investor uncertainty. Article Title
• Negative Sentiment: FDA warning coverage and heightened regulatory scrutiny — Reports cite an FDA warning that focuses attention on ANKTIVA’s regulatory path and company disclosures, amplifying downside risk if further negative findings emerge. Article Title

Analyst Ratings Changes

IBRX has been the subject of a number of recent analyst reports. Jefferies Financial Group boosted their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, December 12th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research note on Monday, February 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. BTIG Research started coverage on shares of ImmunityBio in a research note on Thursday, March 12th. They set a “buy” rating and a $13.00 price objective for the company. Finally, D. Boral Capital restated a “buy” rating and set a $23.00 price objective on shares of ImmunityBio in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, ImmunityBio presently has an average rating of “Moderate Buy” and an average target price of $14.40.

ImmunityBio Stock Performance

The firm has a market cap of $7.59 billion, a PE ratio of -19.42 and a beta of -0.03. The stock has a fifty day moving average price of $7.64 and a 200-day moving average price of $4.19.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The business had revenue of $38.29 million during the quarter. As a group, equities analysts predict that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling at ImmunityBio

In related news, Director Christobel Selecky sold 25,000 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Barry J. Simon sold 75,000 shares of the stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total value of $900,750.00. Following the completion of the sale, the director owned 2,850,821 shares of the company’s stock, valued at approximately $34,238,360.21. This represents a 2.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 501,967 shares of company stock valued at $4,466,412 in the last three months. Company insiders own 69.48% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of ImmunityBio by 18.5% in the fourth quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock worth $64,899,000 after buying an additional 5,122,052 shares during the period. State Street Corp raised its holdings in shares of ImmunityBio by 45.4% during the 4th quarter. State Street Corp now owns 16,455,703 shares of the company’s stock valued at $32,582,000 after buying an additional 5,139,890 shares during the period. Geode Capital Management LLC lifted its position in ImmunityBio by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company’s stock worth $15,684,000 after acquiring an additional 1,030,113 shares in the last quarter. Armistice Capital LLC acquired a new position in ImmunityBio during the 2nd quarter worth approximately $20,497,000. Finally, Heights Capital Management Inc. purchased a new position in ImmunityBio in the 3rd quarter worth approximately $16,152,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.